We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01372579
Recruitment Status : Active, not recruiting
First Posted : June 14, 2011
Last Update Posted : July 6, 2017
Sponsor:
Collaborator:
Eisai Inc.
Information provided by (Responsible Party):
Northwestern University